相关实验视频

Updated: Jun 13, 2025

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

免疫检查点抑制剂在非小细胞肺癌中重新出现:目前的证据和未来的方向

Xiaoyu Gang¹, Jinshan Yan¹, Xin Li¹

¹Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China.

|September 11, 2024

概括

免疫检查点抑制剂 (ICI) 对非小细胞肺癌 (NSCLC) 有好处. 本综述探讨了在停止治疗后重新挑战ICI的患者,并确定了改善结果的策略和生物标志物.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
翻译医学是一种翻译医学.

背景情况:

免疫检查点抑制剂 (ICI) 已经改变了非小细胞肺癌 (NSCLC) 治疗.
由于治疗完成,进展或不良事件,可以中止ICI.
由于持续的免疫反应,重新挑战ICI患者是一个可行的策略.

研究的目的:

系统地审查ICI在NSCLC中的临床证据.
将重新挑战场景分类,并探索克服阻力的方法.
确定患者选择的生物标志物,并提供实际指导方针.

主要方法:

对现有的临床研究证据进行系统分析.
对ICI的分类重新挑战到不同的临床场景.
探索克服ICI耐药性的策略,并识别预测生物标志物.

主要成果:

在初始停止治疗后,ICI重新挑战是NSCLC患者的可行选择.
存在各种策略来克服在重新挑战期间的阻力.
生物标志物可以帮助识别那些将从重新挑战中受益的患者.

结论:

重新挑战ICI为NSCLC患者提供了治疗潜力.
进一步的研究和生物标志物识别对于优化重新挑战策略至关重要.
需要实用指导方针来最大限度地提高NSCLC的免疫疗法益处.

关键词:

免疫检查点抑制剂免疫检查点抑制剂免疫疗法耐药性免疫疗法耐药性美国的伊拉克.在NSCLCLC中,我们可以看到NSCLCLC.重新挑战一个挑战

更多相关视频

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.